SEC Filings

SEC Filings

Filing date	Description	Form	View
Aug 16, 2021	Quarterly report which provides a continuing view of a company's financial position	10-Q	View HTML 0001558370-21-011785.pdf 0001558370-21-011785.rtf 0001558370-21-011785.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Nov 12, 2021	Quarterly report which provides a continuing view of a company's financial position	10-Q	View HTML 0001558370-21-015766.pdf 0001558370-21-015766.rtf 0001558370-21-015766.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
May 23, 2022	Quarterly report which provides a continuing view of a company's financial position	10-Q	View HTML 0001558370-22-009259.pdf 0001558370-22-009259.rtf 0001558370-22-009259.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Aug 19, 2022	Quarterly report which provides a continuing view of a company's financial position	10-Q	View HTML 0001558370-22-013821.pdf 0001558370-22-013821.rtf 0001558370-22-013821.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Nov 14, 2022	Quarterly report which provides a continuing view of a company's financial position	10-Q	View HTML 0001558370-22-017869.pdf 0001558370-22-017869.rtf 0001558370-22-017869.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
May 15, 2023	Quarterly report which provides a continuing view of a company's financial position	10-Q	View HTML 0001558370-23-009920.pdf 0001558370-23-009920.rtf 0001558370-23-009920.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Aug 07, 2023	Quarterly report which provides a continuing view of a company's financial position	10-Q	View HTML 0001558370-23-013645.pdf 0001558370-23-013645.rtf 0001558370-23-013645.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Nov 09, 2023	Quarterly report which provides a continuing view of a company's financial position	10-Q	View HTML 0001558370-23-018344.pdf 0001558370-23-018344.rtf 0001558370-23-018344.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Aug 03, 2012	Amendment to a previously filed 10-Q	10-Q/A	View HTML 0001193125-12-335092.pdf 0001193125-12-335092.rtf 0001193125-12-335092.xls
Jun 22, 2021	Termination of registration under Section 12(g) or suspension of duty to file reports	15-12B	View HTML 0001104659-21-084121.pdf 0001104659-21-084121.rtf 0001104659-21-084121.xls

Data provided by Kaleidoscope.

For investor inquiries, please contact:

ReShape Lifesciences Investor Contact:
Thomas Stankovich
Chief Financial Officer
949-276-6042
ir@ReShapeLifesci.com

Investor Contacts:
Rx Communications Group
Michael Miller
917-633-6086
mmiller@rxir.com

PRINT PAGE

EMAIL PAGE